<DOC>
	<DOCNO>NCT00580125</DOCNO>
	<brief_summary>The objective study demonstrate efficacy dose-response treatment acute exacerbation schizophrenia comparison placebo .</brief_summary>
	<brief_title>Dose-response Study Evaluate Safety , Efficacy , Pharmacokinetics PF-00217830 Compared With Placebo Acute Exacerbation Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Key inclusion criterion include : Have current diagnosis schizophrenia . Increase symptoms past 24 week . Willing remain inpatient duration trial . Subjects current DSMIV axis I diagnosis schizophrenia Subjects meet DSMIV criterion psychoactive substance abuse dependence Subjects history treatment resistant schizophrenia Females childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>